Relapsed Acute Myeloid Leukemia Drug and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Relapsed Acute Myeloid Leukemia Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Relapsed Acute Myeloid Leukemia Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Relapsed Acute Myeloid Leukemia Drug Overall Market Size
2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size: 2021 VS 2028
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales: 2017-2028
3 Company Landscape
3.1 Top Relapsed Acute Myeloid Leukemia Drug Players in Global Market
3.2 Top Global Relapsed Acute Myeloid Leukemia Drug Companies Ranked by Revenue
3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Companies
3.4 Global Relapsed Acute Myeloid Leukemia Drug Sales by Companies
3.5 Global Relapsed Acute Myeloid Leukemia Drug Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Relapsed Acute Myeloid Leukemia Drug Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Players in Global Market
3.8.1 List of Global Tier 1 Relapsed Acute Myeloid Leukemia Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Market Size Markets, 2021 & 2028
4.1.2 aNK Program
4.1.3 AT-9283
4.1.4 BI-836858
4.1.5 Binimetinib
4.1.6 BL-8040
4.1.7 Others
4.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
4.2.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2022
4.2.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2023-2028
4.2.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
4.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
4.3.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2022
4.3.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2023-2028
4.3.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
4.4 By Type - Global Relapsed Acute Myeloid Leukemia Drug Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2021 & 2028
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
5.2.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2022
5.2.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2023-2028
5.2.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
5.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
5.3.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2022
5.3.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2023-2028
5.3.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
5.4 By Application - Global Relapsed Acute Myeloid Leukemia Drug Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2021 & 2028
6.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
6.2.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2022
6.2.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2023-2028
6.2.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
6.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
6.3.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2022
6.3.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2023-2028
6.3.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028
6.4.2 By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028
6.4.3 US Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.4.4 Canada Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.4.5 Mexico Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028
6.5.2 By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028
6.5.3 Germany Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.5.4 France Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.5.5 U.K. Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.5.6 Italy Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.5.7 Russia Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.5.8 Nordic Countries Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.5.9 Benelux Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028
6.6.2 By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028
6.6.3 China Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.6.4 Japan Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.6.5 South Korea Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.6.6 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.6.7 India Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028
6.7.2 By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028
6.7.3 Brazil Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.7.4 Argentina Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028
6.8.3 Turkey Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.8.4 Israel Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.8.5 Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
6.8.6 UAE Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 4SC AG
7.1.1 4SC AG Corporate Summary
7.1.2 4SC AG Business Overview
7.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.1.5 4SC AG Key News
7.2 AbbVie Inc.
7.2.1 AbbVie Inc. Corporate Summary
7.2.2 AbbVie Inc. Business Overview
7.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.2.5 AbbVie Inc. Key News
7.3 Actinium Pharmaceuticals, Inc.
7.3.1 Actinium Pharmaceuticals, Inc. Corporate Summary
7.3.2 Actinium Pharmaceuticals, Inc. Business Overview
7.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.3.5 Actinium Pharmaceuticals, Inc. Key News
7.4 Agios Pharmaceuticals, Inc.
7.4.1 Agios Pharmaceuticals, Inc. Corporate Summary
7.4.2 Agios Pharmaceuticals, Inc. Business Overview
7.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.4.5 Agios Pharmaceuticals, Inc. Key News
7.5 Amgen Inc.
7.5.1 Amgen Inc. Corporate Summary
7.5.2 Amgen Inc. Business Overview
7.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.5.5 Amgen Inc. Key News
7.6 Arog Pharmaceuticals, Inc.
7.6.1 Arog Pharmaceuticals, Inc. Corporate Summary
7.6.2 Arog Pharmaceuticals, Inc. Business Overview
7.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.6.5 Arog Pharmaceuticals, Inc. Key News
7.7 Array BioPharma Inc.
7.7.1 Array BioPharma Inc. Corporate Summary
7.7.2 Array BioPharma Inc. Business Overview
7.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.7.5 Array BioPharma Inc. Key News
7.8 Astellas Pharma Inc.
7.8.1 Astellas Pharma Inc. Corporate Summary
7.8.2 Astellas Pharma Inc. Business Overview
7.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.8.5 Astellas Pharma Inc. Key News
7.9 Astex Pharmaceuticals, Inc.
7.9.1 Astex Pharmaceuticals, Inc. Corporate Summary
7.9.2 Astex Pharmaceuticals, Inc. Business Overview
7.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.9.5 Astex Pharmaceuticals, Inc. Key News
7.10 AstraZeneca Plc
7.10.1 AstraZeneca Plc Corporate Summary
7.10.2 AstraZeneca Plc Business Overview
7.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.10.5 AstraZeneca Plc Key News
7.11 AVEO Pharmaceuticals, Inc.
7.11.1 AVEO Pharmaceuticals, Inc. Corporate Summary
7.11.2 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Business Overview
7.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.11.5 AVEO Pharmaceuticals, Inc. Key News
7.12 BioLineRx, Ltd.
7.12.1 BioLineRx, Ltd. Corporate Summary
7.12.2 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Business Overview
7.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.12.5 BioLineRx, Ltd. Key News
7.13 Boehringer Ingelheim GmbH
7.13.1 Boehringer Ingelheim GmbH Corporate Summary
7.13.2 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Business Overview
7.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.13.5 Boehringer Ingelheim GmbH Key News
7.14 Boston Biomedical, Inc.
7.14.1 Boston Biomedical, Inc. Corporate Summary
7.14.2 Boston Biomedical, Inc. Business Overview
7.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.14.5 Boston Biomedical, Inc. Key News
7.15 Bristol-Myers Squibb Company
7.15.1 Bristol-Myers Squibb Company Corporate Summary
7.15.2 Bristol-Myers Squibb Company Business Overview
7.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.15.5 Bristol-Myers Squibb Company Key News
7.16 Calithera Biosciences, Inc.
7.16.1 Calithera Biosciences, Inc. Corporate Summary
7.16.2 Calithera Biosciences, Inc. Business Overview
7.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.16.5 Calithera Biosciences, Inc. Key News
7.17 Celgene Corporation
7.17.1 Celgene Corporation Corporate Summary
7.17.2 Celgene Corporation Business Overview
7.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.17.5 Celgene Corporation Key News
7.18 Cornerstone Pharmaceuticals, Inc.
7.18.1 Cornerstone Pharmaceuticals, Inc. Corporate Summary
7.18.2 Cornerstone Pharmaceuticals, Inc. Business Overview
7.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.18.5 Cornerstone Pharmaceuticals, Inc. Key News
7.19 CTI BioPharma Corp.
7.19.1 CTI BioPharma Corp. Corporate Summary
7.19.2 CTI BioPharma Corp. Business Overview
7.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
7.19.5 CTI BioPharma Corp. Key News
8 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity, Analysis
8.1 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity, 2017-2028
8.2 Relapsed Acute Myeloid Leukemia Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Relapsed Acute Myeloid Leukemia Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Relapsed Acute Myeloid Leukemia Drug Supply Chain Analysis
10.1 Relapsed Acute Myeloid Leukemia Drug Industry Value Chain
10.2 Relapsed Acute Myeloid Leukemia Drug Upstream Market
10.3 Relapsed Acute Myeloid Leukemia Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Relapsed Acute Myeloid Leukemia Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
List of Tables
Table 1. Key Players of Relapsed Acute Myeloid Leukemia Drug in Global Market
Table 2. Top Relapsed Acute Myeloid Leukemia Drug Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Companies, 2017-2022
Table 5. Global Relapsed Acute Myeloid Leukemia Drug Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Relapsed Acute Myeloid Leukemia Drug Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
Table 9. List of Global Tier 1 Relapsed Acute Myeloid Leukemia Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2017-2022
Table 15. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2023-2028
Table 16. By Application ? Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2017-2022
Table 20. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2023-2028
Table 21. By Region ? Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2017-2022
Table 25. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2023-2028
Table 26. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028
Table 46. 4SC AG Corporate Summary
Table 47. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 48. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. AbbVie Inc. Corporate Summary
Table 50. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 51. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Actinium Pharmaceuticals, Inc. Corporate Summary
Table 53. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 54. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. Agios Pharmaceuticals, Inc. Corporate Summary
Table 56. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 57. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. Amgen Inc. Corporate Summary
Table 59. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 60. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. Arog Pharmaceuticals, Inc. Corporate Summary
Table 62. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 63. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. Array BioPharma Inc. Corporate Summary
Table 65. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 66. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. Astellas Pharma Inc. Corporate Summary
Table 68. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 69. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Astex Pharmaceuticals, Inc. Corporate Summary
Table 71. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 72. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. AstraZeneca Plc Corporate Summary
Table 74. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 75. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. AVEO Pharmaceuticals, Inc. Corporate Summary
Table 77. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 78. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. BioLineRx, Ltd. Corporate Summary
Table 80. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 81. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. Boehringer Ingelheim GmbH Corporate Summary
Table 83. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 84. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Boston Biomedical, Inc. Corporate Summary
Table 86. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 87. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 88. Bristol-Myers Squibb Company Corporate Summary
Table 89. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 90. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 91. Calithera Biosciences, Inc. Corporate Summary
Table 92. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 93. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 94. Celgene Corporation Corporate Summary
Table 95. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 96. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 97. Cornerstone Pharmaceuticals, Inc. Corporate Summary
Table 98. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 99. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 100. CTI BioPharma Corp. Corporate Summary
Table 101. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 102. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 103. Relapsed Acute Myeloid Leukemia Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 104. Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share of Key Manufacturers, 2020-2022
Table 105. Global Relapsed Acute Myeloid Leukemia Drug Production by Region, 2017-2022 (K Pcs)
Table 106. Global Relapsed Acute Myeloid Leukemia Drug Production by Region, 2023-2028 (K Pcs)
Table 107. Relapsed Acute Myeloid Leukemia Drug Market Opportunities & Trends in Global Market
Table 108. Relapsed Acute Myeloid Leukemia Drug Market Drivers in Global Market
Table 109. Relapsed Acute Myeloid Leukemia Drug Market Restraints in Global Market
Table 110. Relapsed Acute Myeloid Leukemia Drug Raw Materials
Table 111. Relapsed Acute Myeloid Leukemia Drug Raw Materials Suppliers in Global Market
Table 112. Typical Relapsed Acute Myeloid Leukemia Drug Downstream
Table 113. Relapsed Acute Myeloid Leukemia Drug Downstream Clients in Global Market
Table 114. Relapsed Acute Myeloid Leukemia Drug Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Relapsed Acute Myeloid Leukemia Drug Segment by Type
Figure 2. Relapsed Acute Myeloid Leukemia Drug Segment by Application
Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Relapsed Acute Myeloid Leukemia Drug Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028 (US$, Mn)
Figure 7. Relapsed Acute Myeloid Leukemia Drug Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Relapsed Acute Myeloid Leukemia Drug Revenue in 2021
Figure 9. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
Figure 10. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
Figure 11. By Type - Global Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
Figure 13. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
Figure 14. By Application - Global Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
Figure 16. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
Figure 17. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
Figure 18. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
Figure 19. US Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
Figure 24. Germany Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 25. France Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
Figure 33. China Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 37. India Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
Figure 39. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
Figure 40. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
Figure 44. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2017-2028
Figure 48. Global Relapsed Acute Myeloid Leukemia Drug Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Relapsed Acute Myeloid Leukemia Drug by Region, 2021 VS 2028
Figure 50. Relapsed Acute Myeloid Leukemia Drug Industry Value Chain
Figure 51. Marketing Channels
Industry Market Size
